Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations /631/67/1612/1350 /692/4028/67/1059/2326 /692/4028/67/1059/602 /119 /129 /141 article

Metastatic non-small-cell lung cancer (NSCLC) with activating EGFR mutations responds very well to first and second generation tyrosine-kinase inhibitors (TKI) including gefitinib, erlotinib and afatinib. Unfortunately, drug resistance will eventually develop and about half of the cases are secondary to the emergence of acquired T790M somatic mutation. In this work, we prospectively recruited 68 patients with metastatic EGFR-mutated NSCLC who have developed progressive disease after first-line TKI with or without subsequent TKI and/or other systemic therapy. Liquid biopsy after progression to their last line of systemic therapy were taken for detection of acquired T790M mutation. By performing attribute ranking we found that several attributes, including the initial EGFR mutational type, had a high correlation with the presence of acquired T790M mutation. We also conducted computational studies and discovered that the EGFR mutation delE746-A750 had a lower stability around the residue T790 than delS752-I759 and L858R, which was consistent with our clinical observation that patients with delE746-A750 were more likely to acquire T790M mutation than those with delS752-I759 or L858R. Our results provided new insight to future direction of research on investigating the mechanisms of acquired T790M mutation, which is essential to the development of novel mutation-specific TKIs.